Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when HRMY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer departed effective July 16, 2026, to pursue other career opportunities, creating a leadership transition during a period of strong revenue growth.
Harmony Biosciences CFO Glenn Reicin departs; Q2 revenue hits record $261M, up 30% YoY
Filed July 16, 2026 · Period ending July 16, 2026 · ~1 min read
Key Changes
-
high
CFO Glenn Reicin stepped down effective July 16, 2026, to pursue other opportunities; SVP Stephen Mollichella appointed Interim Principal Financial Officer while the company searches for a permanent CFO.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
high
Preliminary Q2 2026 WAKIX net revenue of approximately $261M represents a quarterly record, up 30% year-over-year and 21% sequentially from Q1 2026, driven by strong demand and commercial execution.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
high
Full-year 2026 net product revenue guidance reaffirmed at $1.0B to $1.04B based on first-half performance and current business trends.
Item 2.02 — Results of Operations and Financial Condition verify on EDGAR → -
medium
Company stated Reicin's departure was not due to any disagreement on operations, policies, or practices, and does not expect the transition to affect performance or momentum.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Harmony Biosciences disclosed the departure of CFO Glenn Reicin effective July 16, 2026, to pursue other opportunities, alongside strong preliminary Q2 2026 results. The company appointed Stephen Mollichella, its SVP and Controller since 2021, as Interim Principal Financial Officer while conducting a search for a permanent CFO.
Reicin's departure was not due to any disagreement with the company, and management stated it does not expect the transition to affect performance. The CFO transition occurs as Harmony reported record quarterly WAKIX revenue of approximately $261 million for Q2 2026, up 30% year-over-year and 21% sequentially.
The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion, citing strong demand and disciplined commercial execution. While the departure creates a leadership gap during a critical growth phase, the company's decision to promote an internal finance leader with five years of tenure and the explicit no-disagreement disclosure suggest an orderly transition. Investors should monitor the CFO search timeline and whether the interim arrangement extends beyond one or two quarters, which could signal difficulty attracting candidates or internal friction not disclosed in the filing.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 16, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary net product revenue for the second quarter of 2026. In addition, the Company reaffirmed its guidance related to 2026 net product revenue.
The company disclosed preliminary net product revenue results for the second quarter of 2026 and reaffirmed its full-year 2026 net product revenue guidance. The specific revenue figures and guidance ranges are contained in the press release exhibit, which was not provided in the 8-K body text.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Glenn Reicin, the Company’s Chief Financial Officer, will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.
Glenn Reicin resigned as Chief Financial Officer effective July 16, 2026, to pursue other career opportunities. The company entered into a Separation Agreement providing severance payments and benefits per his employment agreement, plus a pro-rated target bonus, in exchange for a release of claims and continued compliance with restrictive covenants.
Added in current filing · verify on EDGAR →
the Board of Directors of the Company appointed Stephen Mollichella, the Company’s Senior Vice President and Controller, as Interim Principal Financial Officer of the Company, effective as of July 16, 2026. Mr. Mollichella brings more than two decades of finance and accounting leadership experience across publicly traded biopharmaceutical and medical technology companies. Since joining the Company in 2021, he has played a key role in leading the Company’s financial accounting and reporting functions, building the Company’s accounting team and key financial systems, overseeing key financial governance and control processes and supporting the Company’s business development activities.
Stephen Mollichella, the company's Senior Vice President and Controller since 2021, was appointed Interim Principal Financial Officer effective July 16, 2026. He has over 20 years of finance and accounting leadership experience in publicly traded biopharmaceutical and medical technology companies and has led the company's financial accounting, reporting, team-building, systems implementation, and governance processes.
Event · Item 7.01 — Regulation FD Disclosure
Harmony Biosciences announced officer changes via press release; details not disclosed in the 8-K body.
Added in current filing · verify on EDGAR →
On July 16, 2026, the Company issued a press release announcing the officer changes discussed above.
The company disclosed officer changes through a press release furnished as Exhibit 99.1. The 8-K body does not specify the nature of the changes, the officers involved, or whether these are departures, appointments, or role modifications. The details are contained in the press release exhibit.
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
Mr. Reicin’s departure is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices, and Harmony does not expect this transition to affect its performance or momentum in any way.
The company explicitly disclosed that the CFO's departure was not due to any disagreement on operations, policies, or practices, and does not expect the transition to affect performance or momentum. This is a standard Item 5.02 disclosure addressing potential investor concerns.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 20, 2026 · How we verify